Profile picture

Mr Madan Raj Poudel

University Clinic OWL, Bielefeld (Germany)
Follow
Logo ESC

Contributor content

Spectacular and unexpected a rare case of a giant thrombosed left ventricular aneurysm after silent myocardial infarction - challenging differential diagnosis of true or false aneurysms
Presentation
Spectacular and unexpected a rare case of a giant thrombosed left ventricular aneurysm after silent myocardial infarction - challenging differential diagnosis of true or false aneurysms
ST-elevation myocardial infarction with unexpected ventricular septal defect, covered rupture & pericardial tamponade managed by combined percutaneous circulatory support as bridge to surgical repair
Presentation
ST-elevation myocardial infarction with unexpected ventricular septal defect, covered rupture & pericardial tamponade managed by combined percutaneous circulatory support as bridge to surgical repair
Extremely elevated lipoprotein (a) as an independent risk factor for peripheral arterial disease in large patient cohort
Presentation
Extremely elevated lipoprotein (a) as an independent risk factor for peripheral arterial disease in large patient cohort
Extremely elevated lipoprotein (a) as an independent risk factor for coronary heart disease in large patient cohort
Presentation
Extremely elevated lipoprotein (a) as an independent risk factor for coronary heart disease in large patient cohort
Real world prospective one year monocentric follow up study investigating novel lipid lowering agents class proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab
Presentation
Real world prospective one year monocentric follow up study investigating novel lipid lowering agents class proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab
Aortic valve stenosis in patients with extremely elevated lipoprotein(a) levels
Presentation
Aortic valve stenosis in patients with extremely elevated lipoprotein(a) levels
First real world experience with the novel lipid-lowering drug PCSK9 inhibitor evolocumab in patients undergoing lipid apheresis: 1-year follow up
Presentation
First real world experience with the novel lipid-lowering drug PCSK9 inhibitor evolocumab in patients undergoing lipid apheresis: 1-year follow up
Safety aspects and side effects of the novel lipid-lowering PCSK9 inhibitors evolocumab /alirozumab in atherosclerotic patients with familial hypercholesterolemia under lipid apheresis
Presentation
Safety aspects and side effects of the novel lipid-lowering PCSK9 inhibitors evolocumab /alirozumab in atherosclerotic patients with familial hypercholesterolemia under lipid apheresis
Efficacy of the PCSK9 inhibitors evolocumab/alirozumab in the reduction of LDL and Lp (a) in patients with familial hypercholesterolemia/manifest atherosclerosis in a real world setting
Presentation
Efficacy of the PCSK9 inhibitors evolocumab/alirozumab in the reduction of LDL and Lp (a) in patients with familial hypercholesterolemia/manifest atherosclerosis in a real world setting
Reduction of LDL and Lp (a) under the PCSK9 inhibitor Evolocumab/Alirozumab in patients with familial hypercholesterolemia or manifest atherosclerosis
Presentation
Reduction of LDL and Lp (a) under the PCSK9 inhibitor Evolocumab/Alirozumab in patients with familial hypercholesterolemia or manifest atherosclerosis

ESC 365 is supported by